Credits: Canva
An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.
One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.
Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.
The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.
The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.
Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”
The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.
Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.
The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.
Credit: iStock
Nearly 20 prescriptions for life-ending medication were reportedly issued in New York during the first month of its Medical Aid in Dying (MAiD) law, according to a Columbia University bioethics expert.
However, state health officials have not yet released data showing how many patients actually used the medication.
New York’s Medical Aid in Dying Act took effect on August 5, making it the 14th US state to legalize medical aid in dying.
David Hoffman, assistant professor of professional practice in bioethics at Columbia University, told The New York Post that conversations with doctors, hospitals and organizations indicated that about 20 prescriptions had been issued since the law took effect.
“The state will have the data on a rolling basis. It’s an after-the-fact analysis,” Hoffman told The Post.
The New York State Department of Health has yet to release precise figures on the program’s use.
Read More: Supreme Court Allows 1st Passive Euthanasia For Man In Vegetative State For 13 Years
The lack of publicly available data has drawn criticism from lawmakers who opposed the law. Upstate Republican Assemblyman Andrew Molitor told The New York Sun that New Yorkers should know how many people have requested and used medical aid in dying.
He said information should include patients’ socioeconomic status, insurance coverage, terminal condition, when prescriptions were filled and where the medication was administered.
Western New York Republican state Sen. George Borrello also criticized the wait for the state’s first annual report.
Critics have additionally raised concerns about whether the law could eventually be expanded. Borrello pointed to Canada, where medical assistance in dying was legalized in 2016.
Medical aid in dying remains controversial because it raises ethical, religious and moral questions. Critics warn about the potential coercion of vulnerable patients, while supporters emphasize personal autonomy and relief from prolonged, incurable suffering.
Medical aid in dying generally involves a patient voluntarily taking lethal medication prescribed by a doctor. Euthanasia, by contrast, involves a healthcare professional administering the lethal medication at the patient’s request.
Under New York’s law, patients must:
The law also requires a five-day waiting period between obtaining and dispensing the prescription.
Medical aid in dying requires the patient to take the prescribed medication themselves. This differs from euthanasia, in which a healthcare professional administers the life-ending medication.
Also read: Can Right To Die Be Practiced By Non-Terminally Ill Patients?
The law requires the state health commissioner to submit an annual report to the Legislature detailing the program’s use.
Hoffman noted that doctors report when medication is prescribed, but the state may not immediately know whether a patient ultimately takes it.
A New York State Department of Health spokesperson told The Post that the department will publish an annual report with utilization data as required by law.
Health Commissioner Dr. James McDonald said end-of-life decisions are “deeply personal” and should be made individually in consultation with patients, doctors, families and loved ones. The department has also issued guidance and proposed regulations intended to prevent misuse or inappropriate application of the law.
The debate over medical aid in dying extends beyond New York and the US.
France’s National Assembly recently gave final approval to a bill that would allow certain adults with incurable illnesses to receive lethal medication, following years of debate over end-of-life care.
Assisted-dying legislation is also being debated in the UK, where a bill covering England and Wales is returning to Parliament.
Credit: FDA/iStock
Vitruvias Therapeutics’ thyroid medication, recalled nationwide in August, has been elevated to the highest risk level by the US FDA.
The recall was issued because the medication may be superpotent, potentially causing hyperthyroidism (overactive thyroid).
On Wednesday, the FDA updated the recall to Class I, its most serious recall classification. It applies when there is a “reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”
Also read: US Cancer Death Rates Fall For Men, Women: Lung Cancer Progress Drives Decline
The affected product is:
In its August 24 recall notice, the company said the tablets were potentially superpotent.
Millions of people with hypothyroidism rely on thyroid tablets every day to replace hormones their bodies cannot produce.
However, taking superpotent thyroid tablets can cause hyperthyroidism (overactive thyroid). It can force the body's metabolism into overdrive, speeding up organs and bodily functions.
Left untreated, this constant strain can cause serious health complications across multiple systems in the body.
In addition, people taking the medication can be at risk of
The lot was distributed nationwide in the US to Vitruvias Therapeutics’ direct accounts between January 31 and September 30, 2025. Of 3,655 units released, 1,955 were sold.
Read More: FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know
The company identified the following groups as being at greater risk from superpotent thyroid tablets:
Excess thyroid hormones in older adults have been associated with adverse outcomes, particularly those affecting the heart.
Vitruvias Therapeutics said it has not received any reports of adverse events known to be linked to the recall.
The company is notifying wholesalers to stop distributing the recalled product and arranging for its destruction.
Patients taking Thyroid, USP from Lot 504950 should not stop taking it without first contacting their healthcare provider for guidance and/or a replacement prescription.
Speaking to HealthandMe, Dr Shruti Kotangale, Consultant Gynaecologist, Obstetrician and Infertility Expert at AIMS Hospital, Dombivli, explained that both conditions are commonly seen in women.
Hypothyroidism occurs when the thyroid is underactive. Symptoms can include tiredness, weight gain, dry skin, hair fall, constipation, feeling cold, a slow heartbeat and low mood or depression.
Hyperthyroidism occurs when the thyroid is overactive. Symptoms may include weight loss, a fast heartbeat, sweating, anxiety, tremors, irritability, frequent bowel movements and difficulty sleeping.
Women should seek medical attention and manage these symptoms without delay.
Thyroid disorders may cause a range of symptoms, including:
Diagnosis may involve:
Credit: Reuters
American racing champion and NASCAR Hall of Famer Darrell Waltrip has been diagnosed with Frontotemporal Dementia (FTD), his family has announced.
The 79-year-old former NASCAR driver and broadcaster will be stepping further away from public life following the diagnosis.
According to his family, Waltrip has FTD, which is being complicated by possible chronic traumatic encephalopathy (CTE), which they believe may be linked to injuries sustained during his racing career from 1972 to 2000.
“We wanted to share a health update with all of Darrell’s friends and fans who have supported him throughout his racing career. Recently, Darrell has been diagnosed with Frontotemporal Degeneration (FTD) complicated by possible Chronic Traumatic Encephalopathy (CTE) — likely from injuries incurred during his racing career,” the family said in a statement.
The family said Waltrip currently has only “minor noticeable symptoms” and is “happy and otherwise healthy,” spending time with his wife, Stevie, and their two daughters.
Chronic traumatic encephalopathy (CTE) is a progressive brain disease believed to be associated with repeated head injuries. It has most commonly been studied in contact-sport athletes and military personnel exposed to repeated head trauma.
Experts are still studying how the number and severity of head injuries contribute to CTE risk. Importantly, not everyone exposed to repeated head injuries develops CTE, and the condition can currently be definitively diagnosed only after death through examination of brain tissue.
A 2026 study led by researchers at Boston University and Harvard Medical School found that roughly one in four former NFL players who died between 2016 and 2021 had CTE.
Although CTE has historically received considerable attention in American football and other contact sports, repeated head impacts can occur in motorsports as well.
Waltrip is not alone. NASCAR Hall of Famer Fred Lorenzen was diagnosed with CTE by researchers after he died in 2024.
Read More: The First Symptom of Bruce Willis’ Frontotemporal Dementia That Left His Wife Emma Heming Stunned
Frontotemporal degeneration, also known as frontotemporal dementia (FTD), refers to a group of brain disorders that primarily affect the frontal and temporal lobes.
These areas are involved in personality, behavior, language, and other functions. Unlike Alzheimer's disease, memory loss may not be the first or most prominent symptom of FTD.
FTD can develop at a younger age than many other forms of dementia, sometimes affecting people in their 40s or 50s.
The condition can cause changes in:
Symptoms vary depending on which areas of the brain are most affected and generally worsen over time.
Behavioral Symptoms
Waltrip is one of NASCAR's most accomplished drivers, with 84 Cup Series victories and three Cup Series championships.
He won the Daytona 500 in 1989 and the Southern 500 in 1992. He also won the Coca-Cola 600 five times, making him the winningest driver in the race's history.
Waltrip later became a familiar voice in NASCAR broadcasting, working as a commentator for many years.
© $2026 Times Horizon Private Limited